Free Trial

Organon & Co. (OGN) Competitors

Organon & Co. logo
$9.99 +0.09 (+0.86%)
As of 11:46 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

OGN vs. BPMC, BBIO, VRNA, ROIV, ELAN, RVMD, LEGN, GRFS, TGTX, and LNTH

Should you be buying Organon & Co. stock or one of its competitors? The main competitors of Organon & Co. include Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry.

Organon & Co. vs. Its Competitors

Organon & Co. (NYSE:OGN) and Blueprint Medicines (NASDAQ:BPMC) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

77.4% of Organon & Co. shares are held by institutional investors. 2.0% of Organon & Co. shares are held by insiders. Comparatively, 4.2% of Blueprint Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Organon & Co. currently has a consensus price target of $18.00, indicating a potential upside of 80.09%. Blueprint Medicines has a consensus price target of $128.25, indicating a potential downside of 0.82%. Given Organon & Co.'s stronger consensus rating and higher probable upside, equities analysts clearly believe Organon & Co. is more favorable than Blueprint Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Organon & Co.
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.50
Blueprint Medicines
0 Sell rating(s)
17 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.24

Organon & Co. has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500.

Organon & Co. has a net margin of 11.92% compared to Blueprint Medicines' net margin of -27.70%. Organon & Co.'s return on equity of 227.43% beat Blueprint Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Organon & Co.11.92% 227.43% 7.34%
Blueprint Medicines -27.70%-64.60%-17.22%

In the previous week, Organon & Co. had 47 more articles in the media than Blueprint Medicines. MarketBeat recorded 55 mentions for Organon & Co. and 8 mentions for Blueprint Medicines. Blueprint Medicines' average media sentiment score of 0.99 beat Organon & Co.'s score of 0.13 indicating that Blueprint Medicines is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Organon & Co.
4 Very Positive mention(s)
5 Positive mention(s)
40 Neutral mention(s)
3 Negative mention(s)
3 Very Negative mention(s)
Neutral
Blueprint Medicines
6 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Organon & Co. has higher revenue and earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Organon & Co.$6.40B0.41$864M$2.883.47
Blueprint Medicines$508.82M16.41-$67.09M-$2.47-52.35

Summary

Organon & Co. beats Blueprint Medicines on 11 of the 16 factors compared between the two stocks.

Get Organon & Co. News Delivered to You Automatically

Sign up to receive the latest news and ratings for OGN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OGN vs. The Competition

MetricOrganon & Co.Medical Services IndustryMedical SectorNYSE Exchange
Market Cap$2.60B$7.34B$5.59B$20.55B
Dividend Yield0.80%2.80%5.25%3.74%
P/E Ratio3.4727.1527.5428.00
Price / Sales0.4134.04415.8340.51
Price / Cash2.0223.6737.0622.25
Price / Book5.466.708.104.60
Net Income$864M$230.16M$3.17B$982.91M
7 Day Performance-0.79%2.05%3.33%0.78%
1 Month Performance-0.40%2.30%3.54%4.24%
1 Year Performance-49.82%43.94%33.62%14.43%

Organon & Co. Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OGN
Organon & Co.
4.8944 of 5 stars
$10.00
+0.9%
$18.00
+80.1%
-50.0%$2.60B$6.40B3.474,000Trending News
BPMC
Blueprint Medicines
1.5469 of 5 stars
$128.18
+0.1%
$128.06
-0.1%
+11.5%$8.28B$562.12M-51.89640Insider Trade
BBIO
BridgeBio Pharma
4.6926 of 5 stars
$43.18
-3.7%
$58.85
+36.3%
+78.9%$8.20B$221.90M-12.23400Analyst Upgrade
Gap Up
High Trading Volume
VRNA
Verona Pharma PLC American Depositary Share
1.7666 of 5 stars
$94.58
+0.8%
$101.10
+6.9%
+514.8%$8.05B$42.28M-47.2930Trending News
Analyst Forecast
ROIV
Roivant Sciences
2.2616 of 5 stars
$11.27
-1.1%
$17.50
+55.3%
+3.6%$7.66B$29.05M-45.08860News Coverage
Analyst Forecast
ELAN
Elanco Animal Health
2.3877 of 5 stars
$14.29
flat
$15.17
+6.1%
+9.1%$7.10B$4.44B19.319,000
RVMD
Revolution Medicines
4.5079 of 5 stars
$36.79
-0.3%
$67.58
+83.7%
-12.3%$6.85B$11.58M-9.20250News Coverage
Positive News
LEGN
Legend Biotech
2.9088 of 5 stars
$35.49
+2.5%
$76.20
+114.7%
-15.5%$6.52B$627.24M-60.152,609Analyst Forecast
GRFS
Grifols
3.5204 of 5 stars
$9.04
+2.0%
$10.30
+13.9%
+12.2%$6.22B$7.81B7.7323,822Analyst Upgrade
Gap Up
TGTX
TG Therapeutics
3.3236 of 5 stars
$35.99
-2.0%
$40.80
+13.4%
+90.5%$5.71B$386.39M149.96290Positive News
Analyst Forecast
LNTH
Lantheus
4.455 of 5 stars
$81.86
+0.5%
$130.50
+59.4%
+7.5%$5.66B$1.53B23.26700Positive News

Related Companies and Tools


This page (NYSE:OGN) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners